Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Variety Of Novel Approaches Marks Next-Gen Cancer Therapies At AACR

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The annual meeting of the American Association for Cancer Research has always been a venue for biotechs to display innovative approaches to treating cancer – perhaps catching the eye of an investor – and the 2011 meeting didn't disappoint.
Advertisement

Related Content

Incyte Further Enhances IO Pipeline With Calithera's Arginase Inhibitor
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
Can Wealth Of Molecular Data Enable Promise Of Chemoprevention?
Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA
Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA

Topics

Advertisement
UsernamePublicRestriction

Register

PS004746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel